LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Stock List・Boston Scientific Corp.

Boston Scientific Corp.

Closed

SectorHealthcare

57.61 1.02

Buy Sell

Overview

Share price change

24h

Current

Min

57.41

Max

57.67

Key metrics
By Trading Economics
Income	669M 1.3B
Sales	-83M 5.2B
P/E Sector Avg	23.398 49.701
EPS	0.8
Profit margin	25.774
Employees	59,000
EBITDA	116M 1.1B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+51.66% upside

Dividends
By Dow Jones
Next Earnings	29 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-7.5B 83B
Previous open	56.59
Previous close	57.61

News Sentiment

By Acuity

26%

74%

59 / 345 Healthcare

Boston Scientific Corp. Chart

Past performance is not a reliable indicator of future results.

Related News

18 May 2026, 11:04 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Buys 34% Stake in MiRus for $1.5 Billion

22 Apr 2026, 11:22 UTC

Earnings

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adjusted EPS View

4 Feb 2026, 16:14 UTC

Earnings

Major Market Movers

Boston Scientific Plunges on Disappointing 1Q Outlook Despite 4Q Earnings Beat

4 Feb 2026, 12:13 UTC

Earnings

Boston Scientific Sees More Growth after Earnings, Sales Rise

6 May 2026, 20:15 UTC

Earnings

Penumbra Not Be Providing Fincl Guidance Due to Pending Acquisition by Boston Scientific >PEN

6 May 2026, 20:07 UTC

Earnings

Penumbra 1Q Rev $374.8M >PEN

6 May 2026, 20:07 UTC

Earnings

Penumbra 1Q EPS 82c >PEN

22 Apr 2026, 11:07 UTC

Earnings

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adj EPS View

22 Apr 2026, 10:32 UTC

Earnings

Boston Scientific Now Sees 2026 Reported Sales Up 7%-8.5%, Organic Sales Up 6.5%-8% >BSX

22 Apr 2026, 10:31 UTC

Earnings

Boston Scientific Sees 2Q Reported Sales Up 5.5%-7.5%, Organic Sales Up 5%-7% >BSX

22 Apr 2026, 10:30 UTC

Earnings

Boston Scientific 1Q Organic Sales Up 9.4% >BSX

22 Apr 2026, 10:30 UTC

Earnings

Boston Scientific 1Q Adj EPS 80c >BSX

22 Apr 2026, 10:30 UTC

Earnings

Boston Scientific 1Q EPS 90c >BSX

22 Apr 2026, 10:30 UTC

Earnings

Boston Scientific 1Q Sales $5.2B >BSX

22 Apr 2026, 10:30 UTC

Earnings

Boston Scientific Sees 2Q Adj EPS 82c-Adj EPS 84c >BSX

22 Apr 2026, 10:30 UTC

Earnings

Boston Scientific Sees FY Adj EPS $3.34-Adj EPS $3.41 >BSX

30 Mar 2026, 15:34 UTC

Market Talk

Boston Scientific Faces Some Slowing Growth Trends -- Market Talk

4 Feb 2026, 21:41 UTC

Earnings

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 Feb 2026, 19:38 UTC

Earnings

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 Feb 2026, 17:32 UTC

Earnings

These Stocks Are Today's Movers: AMD, AbbVie, Eli Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More -- Barrons.com

4 Feb 2026, 15:30 UTC

Earnings

Boston Scientific Earnings Beat Estimates. It's the Worst Stock in the S&P 500 Today. -- Barrons.com

4 Feb 2026, 15:29 UTC

Earnings

These Stocks Are Today's Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More -- Barrons.com

4 Feb 2026, 14:06 UTC

Earnings

Boston Scientific Profit, Sales Rise but Issues Soft Guidance -- Update

4 Feb 2026, 13:58 UTC

Earnings

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 Feb 2026, 13:12 UTC

Earnings

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 Feb 2026, 11:32 UTC

Earnings

Boston Scientific Sees 2026 Sales Up 10.5%-11.5%, Organic Sales Up 10%-11% >BSX

4 Feb 2026, 11:31 UTC

Earnings

Boston Scientific Sees 1Q Sales Up 10.5%-12%, Organic Sales Up 8.5%-10% >BSX

4 Feb 2026, 11:30 UTC

Earnings

Boston Scientific 4Q Organic Sales Up 12.7% >BSX

4 Feb 2026, 11:30 UTC

Earnings

Boston Scientific Sees 2026 Adj EPS $3.43-Adj EPS $3.49 >BSX

4 Feb 2026, 11:30 UTC

Earnings

Boston Scientific Sees 1Q Adj EPS 78c-Adj EPS 80c >BSX

Peer Comparison

Price change

Boston Scientific Corp. Forecast

Price Target

By TipRanks

51.66% upside

12 Months Forecast

Average 87.63 USD 51.66%

High 118 USD

Low 68 USD

Based on 27 Wall Street analysts offering 12 month price targets forBoston Scientific Corp. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

27 ratings

Buy

Hold

Sell

Based on 27 analysts giving stock ratings to Boston Scientific Corp. - Dist in the past 3 months.

Sentiment

By Acuity

59 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.